Table 1.
Demographic and baseline characteristics of the enrolled patients
| Clinicopathological | No. of patients |
|---|---|
| Characteristics | n, (%) |
| Gender | |
| Male | 43 (66.2) |
| Female | 22 (33.8) |
| ECOG performance status score | |
| 0 | 21 (32.3) |
| 1 | 38 (58.5) |
| 2 | 6 (9.2) |
| Primary tumor location | |
| Head | 32 (49.2) |
| Body | 13 (20.0) |
| Tail | 6 (9.2) |
| Multicentric | 14 (21.6) |
| No. of metastatic sites involved | |
| Median | 1 |
| Range | 1–4 |
| Metastatic tumor sites | |
| Liver | 53 (81.5) |
| Lung | 14 (21.5) |
| Lymph nodes | 19 (29.2) |
| Peritoneum | 15 (23.1) |
| Others | 7 (10.8) |
| Cycles of mFOLFIRINOX | |
| Median | 8 |
| Range | 1–12 |
ECOG Eastern Cooperative Oncology Group, mFOLFIRINOX modified 5-fluorouracil, irinotecan, leucovorin, and oxaliplatin